Cencora, Inc. (NYSE:COR) Stock Holdings Trimmed by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lessened its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 271,638 shares of the company's stock after selling 5,439 shares during the period. Wealth Enhancement Advisory Services LLC owned approximately 0.14% of Cencora worth $61,032,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in Cencora in the 4th quarter valued at approximately $478,309,000. Bank of America Corp DE lifted its stake in shares of Cencora by 62.3% in the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock valued at $1,166,944,000 after buying an additional 1,994,256 shares in the last quarter. Castlekeep Investment Advisors LLC bought a new position in shares of Cencora in the fourth quarter valued at $399,508,000. Raymond James Financial Inc. bought a new position in shares of Cencora in the fourth quarter valued at $322,460,000. Finally, Invesco Ltd. lifted its position in shares of Cencora by 20.4% during the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after purchasing an additional 550,246 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Trading Up 0.3%

Shares of NYSE COR traded up $0.80 during mid-day trading on Friday, reaching $291.49. The company had a trading volume of 3,890,003 shares, compared to its average volume of 1,547,067. The business's 50-day moving average is $284.83 and its 200-day moving average is $258.55. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock has a market cap of $56.50 billion, a price-to-earnings ratio of 41.46, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.80 earnings per share. Equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora's dividend payout ratio (DPR) is 25.52%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the sale, the chief executive officer now owns 51,070 shares of the company's stock, valued at approximately $13,022,850. This represents a 8.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,223 shares of company stock valued at $12,369,767 in the last 90 days. 10.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on COR. Wells Fargo & Company raised their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Citigroup increased their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Bank of America upped their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $301.18.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.